|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCARB2 |
Gene summary for SCARB2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCARB2 | Gene ID | 950 |
| Gene name | scavenger receptor class B member 2 | |
| Gene Alias | AMRF | |
| Cytomap | 4q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q14108 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 950 | SCARB2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.57e-04 | -1.95e-01 | 0.0155 |
| 950 | SCARB2 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.58e-11 | 6.27e-01 | -0.1954 |
| 950 | SCARB2 | A015-C-203 | Human | Colorectum | FAP | 4.38e-12 | -2.47e-01 | -0.1294 |
| 950 | SCARB2 | A015-C-204 | Human | Colorectum | FAP | 1.01e-03 | -3.04e-01 | -0.0228 |
| 950 | SCARB2 | A002-C-201 | Human | Colorectum | FAP | 8.34e-08 | -2.43e-01 | 0.0324 |
| 950 | SCARB2 | A001-C-119 | Human | Colorectum | FAP | 9.70e-07 | -3.78e-01 | -0.1557 |
| 950 | SCARB2 | A001-C-108 | Human | Colorectum | FAP | 1.77e-05 | -2.05e-01 | -0.0272 |
| 950 | SCARB2 | A002-C-205 | Human | Colorectum | FAP | 1.64e-14 | -3.71e-01 | -0.1236 |
| 950 | SCARB2 | A015-C-005 | Human | Colorectum | FAP | 1.09e-02 | -2.55e-01 | -0.0336 |
| 950 | SCARB2 | A015-C-006 | Human | Colorectum | FAP | 4.71e-09 | -3.33e-01 | -0.0994 |
| 950 | SCARB2 | A015-C-106 | Human | Colorectum | FAP | 4.41e-04 | -2.15e-01 | -0.0511 |
| 950 | SCARB2 | A002-C-114 | Human | Colorectum | FAP | 2.12e-11 | -3.36e-01 | -0.1561 |
| 950 | SCARB2 | A015-C-104 | Human | Colorectum | FAP | 6.89e-15 | -3.07e-01 | -0.1899 |
| 950 | SCARB2 | A001-C-014 | Human | Colorectum | FAP | 5.96e-07 | -1.78e-01 | 0.0135 |
| 950 | SCARB2 | A002-C-016 | Human | Colorectum | FAP | 4.10e-09 | -2.47e-01 | 0.0521 |
| 950 | SCARB2 | A015-C-002 | Human | Colorectum | FAP | 5.07e-07 | -3.73e-01 | -0.0763 |
| 950 | SCARB2 | A001-C-203 | Human | Colorectum | FAP | 1.29e-04 | -1.84e-01 | -0.0481 |
| 950 | SCARB2 | A002-C-116 | Human | Colorectum | FAP | 1.59e-17 | -2.34e-01 | -0.0452 |
| 950 | SCARB2 | A014-C-008 | Human | Colorectum | FAP | 2.97e-06 | -4.57e-02 | -0.191 |
| 950 | SCARB2 | A018-E-020 | Human | Colorectum | FAP | 1.03e-10 | -2.24e-01 | -0.2034 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00434713 | Esophagus | ESCC | regulation of cellular carbohydrate catabolic process | 11/8552 | 12/18723 | 1.26e-03 | 6.06e-03 | 11 |
| GO:00061096 | Esophagus | ESCC | regulation of carbohydrate metabolic process | 101/8552 | 178/18723 | 1.89e-03 | 8.52e-03 | 101 |
| GO:00106755 | Esophagus | ESCC | regulation of cellular carbohydrate metabolic process | 83/8552 | 146/18723 | 4.24e-03 | 1.69e-02 | 83 |
| GO:00442751 | Esophagus | ESCC | cellular carbohydrate catabolic process | 27/8552 | 40/18723 | 4.39e-03 | 1.73e-02 | 27 |
| GO:00109764 | Esophagus | ESCC | positive regulation of neuron projection development | 91/8552 | 163/18723 | 5.72e-03 | 2.13e-02 | 91 |
| GO:004347010 | Esophagus | ESCC | regulation of carbohydrate catabolic process | 35/8552 | 56/18723 | 8.30e-03 | 2.94e-02 | 35 |
| GO:00160327 | Liver | NAFLD | viral process | 80/1882 | 415/18723 | 7.71e-09 | 1.07e-06 | 80 |
| GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
| GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
| GO:00442623 | Liver | NAFLD | cellular carbohydrate metabolic process | 55/1882 | 283/18723 | 1.27e-06 | 6.01e-05 | 55 |
| GO:00068984 | Liver | NAFLD | receptor-mediated endocytosis | 49/1882 | 244/18723 | 1.80e-06 | 7.78e-05 | 49 |
| GO:00061093 | Liver | NAFLD | regulation of carbohydrate metabolic process | 38/1882 | 178/18723 | 5.71e-06 | 2.04e-04 | 38 |
| GO:00190587 | Liver | NAFLD | viral life cycle | 57/1882 | 317/18723 | 1.00e-05 | 3.18e-04 | 57 |
| GO:00434704 | Liver | NAFLD | regulation of carbohydrate catabolic process | 17/1882 | 56/18723 | 2.17e-05 | 6.02e-04 | 17 |
| GO:00106753 | Liver | NAFLD | regulation of cellular carbohydrate metabolic process | 31/1882 | 146/18723 | 4.47e-05 | 1.08e-03 | 31 |
| GO:00160526 | Liver | NAFLD | carbohydrate catabolic process | 32/1882 | 154/18723 | 5.29e-05 | 1.21e-03 | 32 |
| GO:00444037 | Liver | NAFLD | biological process involved in symbiotic interaction | 50/1882 | 290/18723 | 1.03e-04 | 2.04e-03 | 50 |
| GO:00066233 | Liver | NAFLD | protein targeting to vacuole | 12/1882 | 37/18723 | 1.73e-04 | 3.08e-03 | 12 |
| GO:00313465 | Liver | NAFLD | positive regulation of cell projection organization | 57/1882 | 353/18723 | 2.19e-04 | 3.73e-03 | 57 |
| GO:00160505 | Liver | NAFLD | vesicle organization | 50/1882 | 300/18723 | 2.42e-04 | 4.06e-03 | 50 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414222 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
| hsa0414232 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
| hsa041424 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
| hsa0414211 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
| hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
| hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
| hsa041425 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
| hsa0414212 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
| hsa0414221 | Oral cavity | LP | Lysosome | 67/2418 | 132/8465 | 5.13e-08 | 7.77e-07 | 5.01e-07 | 67 |
| hsa0414231 | Oral cavity | LP | Lysosome | 67/2418 | 132/8465 | 5.13e-08 | 7.77e-07 | 5.01e-07 | 67 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCARB2 | SNV | Missense_Mutation | novel | c.1222G>A | p.Val408Met | p.V408M | Q14108 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A7-A5ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
| SCARB2 | SNV | Missense_Mutation | rs751711805 | c.523G>A | p.Glu175Lys | p.E175K | Q14108 | protein_coding | deleterious(0) | probably_damaging(0.951) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SCARB2 | SNV | Missense_Mutation | c.511C>G | p.His171Asp | p.H171D | Q14108 | protein_coding | deleterious(0) | possibly_damaging(0.702) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| SCARB2 | SNV | Missense_Mutation | c.1173N>T | p.Lys391Asn | p.K391N | Q14108 | protein_coding | deleterious(0.01) | benign(0.14) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SCARB2 | insertion | Nonsense_Mutation | novel | c.509_510insAAAACTATTTTCTTCATCTTGA | p.His171LysfsTer7 | p.H171Kfs*7 | Q14108 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| SCARB2 | insertion | In_Frame_Ins | novel | c.838_839insACAAATTTATTA | p.Ile279_Thr280insAsnLysPheIle | p.I279_T280insNKFI | Q14108 | protein_coding | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| SCARB2 | SNV | Missense_Mutation | rs760128942 | c.469G>A | p.Glu157Lys | p.E157K | Q14108 | protein_coding | tolerated(0.36) | benign(0.345) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SCARB2 | SNV | Missense_Mutation | novel | c.1121G>T | p.Gly374Val | p.G374V | Q14108 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SCARB2 | SNV | Missense_Mutation | rs375205937 | c.628N>A | p.Asp210Asn | p.D210N | Q14108 | protein_coding | deleterious(0.04) | possibly_damaging(0.796) | TCGA-EX-A1H6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SCARB2 | SNV | Missense_Mutation | c.860N>C | p.Val287Ala | p.V287A | Q14108 | protein_coding | deleterious(0) | possibly_damaging(0.626) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |